The *TP53* pathway is crucial for tumour suppression, acting through regulation of cell-cycle control, apoptosis, senescence and DNA repair. The *TP53* gene and its negative regulator *MDM2* are central to this pathway, promoting polyubiquitination and degradation of TP53, and also controlling the TP53 synthesis ([Toledo and Wahl, 2006](#bib19){ref-type="other"}; [Candeias *et al*, 2008](#bib5){ref-type="other"}). Inactivation of the *TP53* pathway has an important role in *BRCA1*- and *BRCA2*-associated tumourigenesis. *BRCA1* and *BRCA2* mutations are associated with genomic instability caused by defective cell-cycle checkpoint and DNA damage repair ([Deng, 2006](#bib8){ref-type="other"}). Mouse model studies have highlighted functional links between these genes. Biallelic inactivation of *BRCA1* and *BRCA2* in mice have shown that embryonic lethality because of growth retardation can be partially rescued in a *Trp53* null background ([Evers and Jonkers, 2006](#bib10){ref-type="other"}). The development of mammary tumours in conditional *BRCA1* and *BRCA2* knockout mice was considerably accelerated in a *Trp53* knockout background ([Evers and Jonkers, 2006](#bib10){ref-type="other"}). In addition, a high incidence of *TP53* mutations has been found in breast tumours of human *BRCA1* and *BRCA2* mutation carriers ([Greenblatt *et al*, 2001](#bib11){ref-type="other"}; [Manie *et al*, 2009](#bib13){ref-type="other"}). The observed interactions between *TP53* and *BRCA* pathways are integral to the progression of tumourigenesis in breast cancer.

A *TP53* polymorphism (rs1042522) has been found to be of functional significance, with the Pro72 allele being less efficient than Arg72 at inducing apoptosis, mainly due to weaker binding and ubiquitination by MDM2 of the Pro72 variant protein ([Dumont *et al*, 2003](#bib9){ref-type="other"}; [Osorio *et al*, 2006](#bib15){ref-type="other"}). An SNP in the promoter region of *MDM2* (309T\>G, rs2279744) has been shown to increase *MDM2* transcriptional activity, thus attenuating the *TP53* pathway ([Bond *et al*, 2004](#bib3){ref-type="other"}). This latter SNP was associated with an earlier onset of breast cancer in Li--Fraumeni patients carrying *TP53* mutations ([Bougeard *et al*, 2006](#bib4){ref-type="other"}; [Ruijs *et al*, 2007](#bib17){ref-type="other"}). The effect on breast cancer risk of the *TP53* Arg72Pro and the *MDM2* 309T\>G polymorphisms, separately and in combination, was investigated in a large case--control study by the Breast Cancer Association Consortium (BCAC), but no association was detected ([Schmidt *et al*, 2007](#bib18){ref-type="other"}). However, several smaller studies examined these polymorphisms in *BRCA1* and *BRCA2* mutation carriers ([Martin *et al*, 2003](#bib14){ref-type="other"}; [Tommiska *et al*, 2005](#bib20){ref-type="other"}; [Copson *et al*, 2006](#bib7){ref-type="other"}; [Osorio *et al*, 2006](#bib15){ref-type="other"}; [Wasielewski *et al*, 2007](#bib21){ref-type="other"}; [Yarden *et al*, 2008](#bib22){ref-type="other"}), and some suggested an association between the *TP53* Pro72 and the *MDM2* 309G alleles with an earlier age at breast cancer diagnosis ([Martin *et al*, 2003](#bib14){ref-type="other"}; [Tommiska *et al*, 2005](#bib20){ref-type="other"}; [Osorio *et al*, 2006](#bib15){ref-type="other"}; [Yarden *et al*, 2008](#bib22){ref-type="other"}). We therefore investigated the associations between breast cancer risk and these *TP53* and *MDM2* polymorphisms in a large series of *BRCA1* and *BRCA2* mutation carriers from the Consortium of Investigators of Modifiers of *BRCA1*/*2* (CIMBA) ([Chenevix-Trench *et al*, 2007](#bib6){ref-type="other"}).

Materials and methods
=====================

Study sample
------------

Eligibility was restricted to female carriers with pathogenic mutations in *BRCA1* or *BRCA2* who were ⩾18 years. Data were obtained from 13 CIMBA studies ([Table 1](#tbl1){ref-type="table"}). The majority of carriers were recruited through cancer genetics clinics offering genetic testing, and enrolled into national or regional studies. Information collected included the year of birth; mutation description; age at last followup; ages at breast and ovarian cancer diagnosis; and age at bilateral prophylactic mastectomy. Information was also available on the country of residence, which was defined to be the country of the clinic at which the carrier family was recruited for the study. Related individuals were identified through a unique family identifier. Further details of the information collected on the *BRCA1* and *BRCA2* mutation carriers and other details of the CIMBA initiative can be found elsewhere. Additional specific acknowledgements to the CIMBA collaborating centres are included in the [Supplementary Appendix](#sup1){ref-type="other"}. (<http://www.srl.cam.ac.uk/consortia/cimba/index.html>) ([Chenevix-Trench *et al*, 2007](#bib6){ref-type="other"}). All carriers participated in clinical and research studies at the host institutions under IRB-approved protocols.

Genotyping
----------

We pooled genotype data from studies within CIMBA that had previously genotyped polymorphisms rs1042522 and rs2279744 (see [Table 1](#tbl1){ref-type="table"}). Deviation from Hardy--Weinberg equilibrium among unrelated subjects was evaluated separately for each SNP and study. There was evidence for deviation for only one study (*P*=0.03), but cluster plot examination did not show any unusual pattern and the study was included in the analysis. Where available study specific genotyping quality control data were examined and data were included if the call rate was over 95% and the concordance among duplicates was over 98%.

Statistical analysis
--------------------

Mutation carriers were classified according to their age at diagnosis of breast cancer or their age at last follow up. For this purpose, individuals were censored at the age of first breast cancer diagnosis, ovarian cancer diagnosis, bilateral prophylactic mastectomy or the age at last observation. Only individuals censored at breast cancer diagnosis were assumed to be affected ([Table 2](#tbl2){ref-type="table"}).

To correct for a potential bias related to the fact that *BRCA1* and *BRCA2* mutation carriers are not randomly sampled with respect to their disease status, the data were analysed within a survival analysis framework, by modelling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes. A detailed description of the retrospective likelihood approach has been published ([Antoniou *et al*, 2007](#bib1){ref-type="other"}). We used a Cox proportional hazards model, where the effect of each SNP was modelled either as a per-allele hazard ratio (HR) or using separate HRs for heterozygotes and homozygotes. To assess the combined effects of the SNPs, we fitted a model in which a separate HR parameter was estimated for each multilocus genotype. More details of the statistical analysis can be found elsewhere ([Antoniou *et al*, 2008](#bib2){ref-type="other"}).

Results
=======

In total, 7011 *BRCA1* and *BRCA2* mutation carriers were genotyped for *TP53* Arg72Pro and 2222 mutation carriers were genotyped for *MDM2* 309T\>G ([Table 1](#tbl1){ref-type="table"}). [Table 2](#tbl2){ref-type="table"} shows summary statistics for the cohort of *BRCA1* and *BRCA2* mutation carriers with an observed genotype for either the *TP53* or *MDM2* polymorphism. There was no evidence of an association between either SNP and breast cancer risk in *BRCA1* or *BRCA2* mutation carriers combined or analysed separately (*TP53* Arg72Pro: *P*~trend~=0.89, 0.77 and 0.83, respectively; *MDM2* 309T\>G: *P*~trend~=0.60, 0.54 and 0.88, respectively) ([Table 3](#tbl3){ref-type="table"}). There was no evidence for heterogeneity in the HRs between studies (*TP53* Arg72Pro: *P*=0.22 and 0.93, *MDM2* 309T\>G: *P*=0.11 and 0.82 for *BRCA1* or *BRCA2* mutation carriers respectively). The HRs for the 9 *TP53--MDM2* combined genotypes, estimated separately in *BRCA1* and *BRCA2* mutation carriers, ranged between 0.72 and 1.31, but none of them were significant.

Discussion
==========

To our knowledge, this is the largest study to investigate the hypothesis that *TP53* Arg72Pro and *MDM2* 309T\>G influence breast cancer risk in *BRCA1* and *BRCA2* mutation carriers individually or in combination. Our findings of no association for these SNPs suggest that they have little or no effect on *BRCA*-related breast cancer risk. These results are consistent with the absence of risk association in the recent *TP53* haplotype analysis, involving Arg72Pro and an intronic polymorphism c.97-147ins16 bp, in a series of 2932 *BRCA1* and *BRCA2* carriers from CIMBA ([Osorio *et al*, 2008](#bib16){ref-type="other"}). Our sample of mutation carriers had power of approximately 75% for *TP53* and 40% for *MDM2* to detect significant associations (*P*\<0.05) for a per-allele HR of 1.1 and power of 100 and 90% respectively for a HR of 1.2, suggesting that we can reliably dismiss previously suggested associations ([Martin *et al*, 2003](#bib14){ref-type="other"}; [Osorio *et al*, 2006](#bib15){ref-type="other"}; [Yarden *et al*, 2008](#bib22){ref-type="other"}).

Yarden *et al* showed that the *MDM2* GG genotype among Ashkenazi *BRCA1/2* mutations carriers was significantly associated with breast cancer diagnosed \<age 51 (*P*=0.019) ([Yarden *et al*, 2008](#bib22){ref-type="other"}). However, we did not find any evidence of an increased risk for the GG homozygotes among the 217 carriers of the *BRCA1* Ashkenazi mutations 185delAG and 5382insC (HR=0.98, 95%CI 0.48--2.01) in this series.

The BCAC study of 5191 cases and 3834 controls found no evidence of an association of *TP53* Arg72Pro and *MDM2* 309T\>G either with breast cancer overall or with oestrogen receptor (ER) status of tumours ([Schmidt *et al*, 2007](#bib18){ref-type="other"}). As the majority of *BRCA1* mutation-associated breast tumours are ER-negative ([Lakhani *et al*, 2005](#bib12){ref-type="other"}), the absence of an association in our study of breast cancer with the *TP53* and *MDM2* SNPs in *BRCA1* mutation carriers is consistent with the lack of an association with ER-negative cancers in the general population.
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###### 

Number of *BRCA1* and *BRCA2* mutation carriers by study and by single nucleotide polymorphism (SNP)

  **Study**                                                                                           **Country**         ***TP53* Arg72Pro (rs1042522)**   ***MDM2* 309T\>G (rs2279744)**   **Genotyping platform**
  --------------------------------------------------------------------------------------------------- ------------------- --------------------------------- -------------------------------- ----------------------------------------------------------------------------------
  Spanish National Cancer Centre (CNIO)                                                               Spain               788                               0                                Restriction enzyme digestion
  Deutsches Krebsforschungszentrum (DKFZ)                                                             Germany             170                               0                                PCR-based RFLP
  Epidemiological study of *BRCA1* and *BRCA2* mutation carriers (EMBRACE)                            U.K. and Eire       1131                              0                                iPLEX
  Genetic Modifiers of cancer risk in *BRCA1/2* mutation carriers (GEMO)                              France and U.S.A.   1405                              1357                             Taqman
  German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC)                                 Germany             815                               0                                Taqman
  Helsinki Breast Cancer Study (HEBCS)                                                                Finland             188                               187                              rs1042522: Amplifluor(tm) fluorescent genotyping (Kbiosciences); rs2279744: RFLP
  HEreditary Breast and Ovarian study Netherlands (HEBON)                                             The Netherlands     438                               432                              Taqman
  INterdisciplinary HEalth Research International Team BReast CAncer susceptibility (INHERIT BRCAs)   Quebec-Canada       146                               155                              Taqman
  kConFab                                                                                             Australia           790                               0                                iPLEX
  National Cancer Institute (NCI)                                                                     USA                 190                               0                                Taqman
  National Israeli Cancer Control Center (NICCC)                                                      Israel              470                               0                                Taqman
  Ontario Cancer Genetics Network (OCGN)                                                              Canada              84                                91                               Taqman
  University of Pennsylvania (UPENN)                                                                  USA                 396                               0                                iPLEX
  Total                                                                                                                   7011                              2222                              

###### 

Summary characteristics for the 7109 eligible *BRCA1* and *BRCA2* carriers used in the analysis and typed for either single nucleotide polymorphism (SNP)

                                     ***BRCA1***   ***BRCA2***                
  --------------------------------- ------------- ------------- ------------- -------------
  Number                                2055          2567          1051          1436
  Person-years follow-up               87 571        104 679       46 315        63 080
  Median age at censure (IQR)        41 (33--51)   40 (34--46)   42 (34--52)   43 (37--50)
                                                                                     
  *Age at censure (years), N* (%)                                             
   \<30                              327 (15.9)     225 (8.8)    139 (13.2)     78 (5.4)
   30--39                            584 (28.4)    1052 (41.0)   296 (28.1)    462 (32.2)
   40--49                            574 (27.9)    880 (34.3)    286 (27.2)    511 (35.6)
   50--59                            364 (17.7)    296 (11.5)    196 (18.7)    278 (19.4)
   60--69                             134 (6.5)     87 (3.4)      82 (7.8)      81 (5.6)
   70+                                72 (3.5)      27 (1.0)      52 (4.9)      26 (1.8)
                                                                                     
  *Year of birth, N* (%)                                                      
   \<1920                             18 (0.9)      32 (1.3)      12 (1.1)      10 (0.7)
   1920--29                           63 (3.1)      117 (4.6)     39 (3.7)      83 (5.8)
   1930--39                           171 (8.3)    267 (10.4)     96 (9.1)     196 (13.7)
   1940--49                          326 (15.9)    657 (25.6)    143 (13.6)    358 (24.9)
   1950--59                          481 (23.4)    820 (31.9)    241 (22.9)    459 (32.0)
   1960+                             996 (48.5)    674 (26.3)    520 (49.5)    330 (23.0)

Abbreviation: IQR=interquartile range.

###### 

Genotype frequencies by mutant gene and breast cancer status with hazard ratio (HR) estimates

                                 **Unaffected (%)**   **Affected (%)**   **HR**   **95% CI**   ***P*-value**
  ------------------------------ -------------------- ------------------ -------- ------------ ---------------
  *TP53 Arg72Pro (rs1042522)*                                                                  
   *BRCA1*/2                                                                                   
    GG                           1660 (54.4)          2164 (54.7)        1.00                   
    GC                           1178 (38.6)          1508 (38.1)        1.00     0.92--1.10    
    CC                           214 (7.0)            287 (7.3)          1.01     0.85--1.20    
    2-df test                                                                                  0.99
    Per allele                                                           1.01     0.94--1.08   0.89
                                                                                                
   *BRCA1*                                                                                     
    GG                           1127 (56.0)          1399 (55.2)        1.00                   
    GC                           748 (37.2)           947 (37.4)         1.01     0.90--1.13    
    CC                           138 (6.9)            188 (7.4)          1.03     0.84--1.27    
    2-df test                                                                                  0.96
    Per allele                                                           1.01     0.93--1.10   0.77
                                                                                                
   *BRCA2*                                                                                     
    GG                           533 (51.3)           765 (53.7)         1.00                   
    GC                           430 (41.4)           561 (39.4)         0.98     0.84--1.14    
    CC                           76 (7.3)             99 (6.9)           0.99     0.72--1.36    
    2-df test                                                                                  0.95
    Per allele                                                           0.99     0.87--1.12   0.83
                                                                                                
  *MDM2 309T*\>*G (rs2279744)*                                                                 
   *BRCA1/2*                                                                                   
    TT                           358 (40.3)           530 (39.8)         1.00                   
    TG                           405 (45.6)           615 (46.1)         0.99     0.84--1.18    
    GG                           126 (14.2)           188 (14.1)         0.93     0.73--1.17    
    2-df test                                                                                  0.79
    Per allele                                                           0.97     0.87--1.08   0.60
                                                                                                
   *BRCA1*                                                                                     
    TT                           275 (39.7)           369 (39.5)         1.00                   
    TG                           323 (46.6)           443 (47.4)         0.98     0.81--1.19    
    GG                           95 (13.7)            123 (13.2)         0.91     0.67--1.19    
    2-df test                                                                                  0.78
    Per allele                                                           0.96     0.84--1.09   0.54
                                                                                                
   *BRCA2*                                                                                     
    TT                           83 (42.4)            161 (40.5)         1.00                   
    TG                           82 (41.8)            172 (43.2)         1.07     0.77--1.50    
    GG                           31 (15.8)            65 (16.3)          0.93     0.60--1.44    
    2-df test                                                                                  0.83
    Per allele                                                           0.98     0.80--1.21   0.88
